Traders work at the New York Stock Exchange on Dec. 29, 2025. NYSE Small-cap U.S. stocks are capping off one of their strongest first halves in decades. But this is not your ordinary small-cap boom led by traditional businesses linked to the economic cycle. This run, like the one going on with their larger-cap peers,…
The U.S. has launched an investigation into Germany’s pharma policies over what it referred to as “persistent underpayment” for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,”…
Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even so, they’re already outlining their visions for the future of obesity drugs. At the American Diabetes Association’s Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots…
Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it can live up to the hype. Icotyde went to market after the Food and Drug Administration approved it in mid-March for moderate to severe plaque psoriasis. The once-a-day drug is the first…
Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty Images Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth. Older top-selling drugs, including its blood thinner…
Pharma thinks it’s found the next frontier in preventing heart attacks. Novartis, Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut Lp(a)…
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off a wave of economic and political uncertainty, some companies are still feeling the effects. While some industries have emerged largely unscathed — having weathered twists and turns of several tariff iterations — others, such as retail, automotive,…
The Trump administration on Thursday imposed new tariffs on branded drugs from pharmaceutical companies that have not struck deals with the president to lower their U.S. drug prices – a long-awaited move that will likely only affect a small portion of drugmakers. “We need to make sure that our drug supply is protected, secure and…
Michael Siluk | UCG | Universal Images Group | Getty Images Novo Nordisk rose as much as 4% after England’s drug price watchdog recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes, marking the first GLP-1 backed for this use in the country. Wegovy is mainly a weight loss treatment…
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday. Centessa is…
